

**APPENDIX A**

1. A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting essentially of: first molecules directed against CD3, and second molecules, distinct from said first molecules, said second molecules directed against CD7, wherein at least one of said first and said second molecules include a toxic moiety.
2. The method according to claim 15, wherein said second molecules specifically recognize CD7.
3. The pharmaceutical composition of claim 1, wherein said first molecules are antibodies.
4. The pharmaceutical composition of claim 1, wherein said second molecules are antibodies.
5. The pharmaceutical composition of claim 1, wherein said toxic moiety is ricin.
6. The pharmaceutical composition of claim 5, wherein said ricin is deglycosylated ricin A.
7. The pharmaceutical composition of claim 1, wherein said toxic moiety is chemically linked to said first and/or second molecules.
8. The pharmaceutical composition of claim 1, wherein said first and second molecules are provided with toxic moieties, which may be the same or different toxic moieties.
10. The pharmaceutical composition of claim 1, wherein said first molecules are gamma2B IgG.
11. The pharmaceutical composition of claim 5, wherein the toxic moiety is at least the equivalent dose of 25 micrograms of ricin A per square meter of body surface of a subject to which the composition is to be administered.
12. The pharmaceutical composition of claim 11, wherein the toxic moiety is at least the equivalent dose of 100 micrograms of ricin A per square meter of the subject's body surface per administration.
13. The pharmaceutical composition of claim 11, wherein the toxic moiety is at most the equivalent dose of 25 mg of ricin A per square meter of the subject's body surface per infusion.
15. A method of treating a disease state in a subject believed to be suffering therefrom, said disease state comprising at least one of Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune disease, said method comprising administering to the subject an amount of a pharmaceutical composition consisting essentially of: first molecules directed against a CD3

positive cell, and second molecules, distinct from said first molecules, directed against a CD7 positive cell, wherein at least the second molecules include a toxic moiety.

18. The pharmaceutical composition of claim 2, wherein said first molecules are antibodies.
19. The pharmaceutical composition of claim 18, wherein said second molecules are antibodies.
20. The pharmaceutical composition of claim 19, wherein said toxic moiety is deglycosylated ricin A.
21. The pharmaceutical composition of claim 19, wherein said toxic moiety is chemically linked to said first and second molecules.
22. The pharmaceutical composition of claim 21, wherein both said first and second molecules are provided with toxic moieties, which may be the same or different toxic moieties.
23. The pharmaceutical composition of claim 18, wherein said first molecules are gamma2B IgG.
24. A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting essentially of: anti-CD3 antibodies; and anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.
25. A method of treating a disease state in a subject believed to be suffering therefrom, said disease state comprising at least one of Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune diseases, said method comprising administering to the subject an amount of a pharmaceutical composition consisting essentially of: anti-CD3 antibodies; and anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.
26. The composition of claim 1, wherein said second molecules include a toxic moiety.

THE PATENT & TRADEMARK OFFICE MAILROOM DATE  
STAMPED HEREON IS AN ACKNOWLEDGEMENT THAT ON THIS  
DATE THE PATENT & TRADEMARK OFFICE RECEIVED:

Brief on Appeal (16 pages); Petition for Extension of Time (1 page);  
Check no. 5606 in the amount of \$210.00

Invention: METHODS AND MEANS FOR THE TREATMENT  
OF IMMUNE RELATED DISEASES  
Applicant(s): van Oosterhout et al.  
Filing Date: September 22, 2000  
Serial No.: 09/668,555  
Date Sent: January 14, 2004 via Express Mail Label No.  
Docket No.: EL994821789US  
ACT/sdd



RECEIVED  
JAN 26 2004  
TRASKBRITT, P.C.

TRASKBRITT  
P.O. Box 2550  
Salt Lake City, UT 84110-2550

RECEIVED  
JAN 26 2004  
TRASKBRITT, P.C.

08/09/2004 13:57 8015319168

WARNING THIS DOCUMENT HAS FLUORESCENT FIBERS.

TRASKBRITT

PAGE 20/24

TRASK BRITT, P.C.  
PATENT ATTORNEYS, CLIENT ADVANCE ACCOUNT  
230 SOUTH 500 EAST, SUITE 300  
P.O. BOX 2550  
SALT LAKE CITY, UT 84102  
PHONE: 801-532-1922

KEY BANK OF UTAH  
SALT LAKE CITY, UT

31-73-1240

560

DATE 01/14/2004

PAY  
EXACTLY Two Hundred Ten AND 00/100 DOLLARS

\$ 210.00

TO THE  
ORDER OF  
Commissioner for Patents

Washington, D.C. 20231

MP  
AUTHORIZED SIGNATURE

1000560610124000737144450400100161

10000021000

08/09/2004 13:57 8015319168

TRASKBRITT

PAGE 21/24

PATENT AND TRADEMARK OFFICE

44-21-2004  
MAILING  
U.S. GOVERNMENT PRINTING OFFICE: 2004-100-000-00000

YOUR ENDORSEMENT IN THE ABOVE AREA ONLY

DO NOT SIGN OR WRITE ON STAMP BELOW THIS LINE

FOR DEPOSITORY BANK USE ONLY

0030 05520

0030 05520

POSTAGE PAID  
WACHOVIA BANK TN 300-071  
PHILADELPHIA, PA 01226004

ATM 2004  
MAILERS 2004  
1221 05278

PROCESSED BY  
PAYOR BANK



The security features on this document include:  
1. The blue ink of the signature area is visible through the paper.  
2. The blue ink of the signature area is visible through the paper.



**Mailing Label**  
Label T1-F June 2002



UNITED STATES POSTAL SERVICE

**Post Office To Addressee**

ORIGIN (POSTAL USE ONLY)		
PO ZIP Code	Day of Delivery	Flat Rate Envelope
	<input type="checkbox"/> Next <input type="checkbox"/> Second <input type="checkbox"/>	
Date In	Postage	
Mo. Day Year	<input type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	\$
Time In	Military Return Receipt Fee	
<input type="checkbox"/> AM <input type="checkbox"/> PM	<input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	
Weight	Intl Alpha Country Code	COD Fee Insurance Fee
Ibs. Ozs.		
No Delivery	Acceptance Clerk Initials	Total Postage & Fees
<input type="checkbox"/> Weekend <input type="checkbox"/> Holiday		\$

DELIVERY (POSTAL USE ONLY)		
Delivery Attempt	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	
Delivery Attempt	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	
Delivery Date	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	

**WANNER OF SIGNATURE** (Check One) Additional charges will be imposed if a handwritten signature is required. If a signature is required, it must be made in black ink or blue ink. A typed name is acceptable if handwritten signatures are not required. Addressed to addressee or agent of addressee. If no employee initials, addressee can be left in secure location and addressed to addressee. Addressee may be a post office box. Addressee may be a business name. Addressee may be a post office box. Addressee may be a business name.

**NO DELIVERY**  Weekdays  Holidays  Other \_\_\_\_\_

Customer Signature

**CUSTOMER USE ONLY**

## METHOD OF PAYMENT:

Express Mail Corporate Acct. No.

**X841812**Federal Agency Acct. No. or  
Postal Service Acct. No.FROM: (PLEASE PRINT) **801 532 1922**

TO: (PLEASE PRINT)

PHONE \_\_\_\_\_

TRASK BRITT LAW OFFICE  
230 S 500 E STE 300  
SALT LAKE CITY UT 84102-2000

MAIL STOP APPEAL BRIEF - PATENTS  
COMMISSIONER FOR PATENTS  
US PATENTS OFFICE  
PO BOX 1450  
ALEXANDRIA VA 22313-1450

PRESS HARD.  
You are making 3 copies.

FOR PICKUP OR TRACKING CALL 1-800-222-1811 [www.usps.com](http://www.usps.com)

THE PATENT & TRADEMARK OFFICE MAILROOM DATE  
STAMPED HEREON IS AN ACKNOWLEDGEMENT THAT ON THIS  
DATE THE PATENT & TRADEMARK OFFICE RECEIVED:

Brief on Appeal (16 pages); Petition for Extension of Time (1 page);  
Check no. 5606 in the amount of \$210.00

Invention: METHODS AND MEANS FOR THE TREATMENT  
OF IMMUNE RELATED DISEASES  
Applicant(s): van Oosterhout et al.  
Filing Date: September 22, 2000  
Serial No.: 09/668,555  
Date Sent: January 14, 2004 via Express Mail Label No.  
Docket No.: EL994821789US  
ACT/sdd 2183-4541US

560

## TRASK BRITT, P.C. PATENT ATTORNEYS / CLIENT ADVANCE ACCOUNT

SD

DATE	INVOICE #	REFERENCE	AMOUNT
01/14/2004		Extension for Response Within Second Mon 2183-4541US	210.00
			210.00

WARNING THIS DOCUMENT HAS FLUORESCENT FIBERS, A VOID PANTOGRAPH AND A MICROPRINT SIGNATURE LINE 6

560C

**TRASK BRITT, P.C.**  
**PATENT ATTORNEYS / CLIENT ADVANCE ACCOUNT**  
 230 SOUTH 500 EAST, SUITE 300  
 P.O. BOX 2550  
 SALT LAKE CITY, UT 84102  
 PHONE: 801-532-1922

KEY BANK OF UTAH  
 SALT LAKE CITY, UT

33-7341240

DATE 01/14/2004

PAY EXACTLY Two Hundred Ten AND 00/100 DOLLARS

\$ 210.00

TO THE  
 ORDER OF  
 Commissioner for Patents  
 Washington, D.C. 20231

NP  
AUTHORIZED SIGNATURE

1005606112124000737445010030416